1,081
edits
Changes
From Biolecture.org
no edit summary
<p>Our main proprietary technologies are: </p>
<ul>
<li><a href="index.php?option=com_content&task=view&id=65&Itemid=107"><font color="#0066cc">EpiScreen™</font></a>, an <em>ex-vivo</em> immunological technology with multiple applications including measurment of the immunogenicity potential of biologics or in the determination of the immunotoxicity of NCEs</li> <li><a href="index.php?option=com_content&task=view&id=63&Itemid=104"><font color="#0066cc">Composite Human Antibodies™</font></a>, a novel technology for the generation of non-immunogenic, humanized antibodies with the avoidance of T cell epitopes</li> <li><a href="index.php?option=com_content&task=view&id=64&Itemid=105"><font color="#0066cc">Composite Proteins™</font></a>, a technology platform for the generation of non-immunogenic therapeutic proteins.</li>
</ul>
<span class="article_seperator"> </span> <a href="http://www.antitope.co.uk">http://www.antitope.co.uk</a><br />
<!-- BEGIN: CONTENT SPOTLIGHT --><br /><strong>Antitope Ltd</strong> <br />Babraham Research Campus <br />Babraham <br />Cambridge CB22 3AT <br />United Kingdom<p>Telephone: +44(0) 1223 496190<br />Fax: +44(0) 1223 496191 <br />E-mail: <a href="mailto:info@antitope.co.uk"><font color="#0066cc">info@antitope.co.uk</font></a> <br /><br /><!-- END: CONTENT SPOTLIGHT --></p>
